Abstract:Abstract Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality, underscores the urgent need for enhanced insights into the molecular and cellular mechanisms underlying metastasis, chemoresistance, and the mechanistic backgrounds of individuals whose cancers are prone to migration. The most prevalent signaling cascade governed by multi-kinase inhibitors is the mitogen-activated protein kinase (MAPK) pathway, encompassing the RAS–RAF–MAPK kinase (MEK)–extracellular signal-related kinase (ERK) pathway. RAF kinase is a primary mediator of the MAPK pathway, responsible for the sequential activation of downstream targets, such as MEK and the transcription factor ERK, which control numerous cellular and physiological processes, including organism development, cell cycle control, cell proliferation and differentiation, cell survival, and death. Defects in this signaling cascade are associated with diseases such as cancer. RAF inhibitors (RAFi) combined with MEK blockers represent an FDA-approved therapeutic strategy for numerous RAF -mutant cancers, including melanoma, non-small cell lung carcinoma, and thyroid cancer. However, the development of therapy resistance by cancer cells remains an important barrier. Autophagy, an intracellular lysosome-dependent catabolic recycling process, plays a critical role in the development of RAFi resistance in cancer. Thus, targeting RAF and autophagy could be novel treatment strategies for RAF -mutant cancers. In this review, we delve deeper into the mechanistic insights surrounding RAF kinase signaling in tumorigenesis and RAFi-resistance. Furthermore, we explore and discuss the ongoing development of next-generation RAF inhibitors with enhanced therapeutic profiles. Additionally, this review sheds light on the functional interplay between RAF-targeted therapies and autophagy in cancer.

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

Targeting the multifaceted BRAF in cancer: New directions

BRAF, a target in melanoma

Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review

Targeting RAS/RAF/MEK/ERK Signaling in Metastatic Melanoma

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Targeted Therapy in Melanoma and Mechanisms of Resistance

Current Advances in the Treatment of BRAF-Mutant Melanoma

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma

Targeting the RAF–MEK–ERK pathway in cancer therapy

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies

BRAF mutation and its inhibitors in sarcoma treatment

Targeting RAS-RAF-MEK-ERK Signaling Pathway in Human Cancer: Current Status in Clinical Trials.

Targeting MEK in non-small cell lung cancer

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

The MEK/ERK Network as a Therapeutic Target in Human Cancer

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer